diabetic peripheral neuropathy. Type 2 diabetes mellitus with diabetic polyneuropathy
Conditions
Interventions
Intervention 1: Intervention group: Oral empagliflozin 10 mg daily for 20 weeks along with previous medication regimen. Intervention 2: Control group: Oral placebo tablet daily for 20 weeks along with
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: A minimum of 3 years of history with type 2 diabetes, diagnosed by an endocrinologist, with a stable medication regimen for at least the past year HbA1c < 8% Confirmation of Diabetic Neuropathy with Screening Test
Exclusion criteria
Exclusion criteria: History of hereditary neuropathy or other acquired causes of neuropathy such as hypothyroidism Having any vascular disease such as stroke, varicose veins Patients who have had active foot infections Any history of trauma to limbs, deformity, and amputation Patients who have been treated for neuropathy History of neurological and psychiatric disorders such as epilepsy, mood disorder Pregnancy or lactation Smoking Insulin injection Use of hormonal and estrogenic drugs Liver diseases, kidney diseases, retinopathy, nephropathy, and acute or chronic inflammation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Michigan Neuropathy Screening Instrument score. Timepoint: Measurement of Michigan Neuropathy Screening Instrument scores at the beginning of the study and 20 weeks after the start of the intervention. Method of measurement: Michigan Neuropathy Screening Instrument questionnaire and clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood gloucose. Timepoint: Measurement of blood gloucose at the beginning of the study and 20 weeks after the start of the intervention. Method of measurement: Patient's blood test.;Blood creatinine. Timepoint: Measurement of blood creatinine at the beginning of the study and 20 weeks after the start of the intervention. Method of measurement: Patient's blood test.;HbA1c. Timepoint: Measurement of HbA1c at the beginning of the study and 20 weeks after the start of the intervention. Method of measurement: Patient's blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Mirzai Malek Abad
Yazd University of Medical Sciences
Outcome results
None listed